Nov 18 (Reuters) - Dogwood Therapeutics Inc :
* DOGWOOD THERAPEUTICS, INC. ANNOUNCES LOW DOSE IMC-2 TREATMENT REDUCES LONG-COVID RELATED FATIGUE AND SLEEP DISTURBANCE IN AN INVESTIGATOR-INITIATED STUDY
* DOGWOOD THERAPEUTICS INC - IMC-2 SHOWS ROBUST REDUCTION IN FATIGUE
Source text: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))